Peer-reviewedCC BY-NC-ND 4.0Nature Communications
Olaparib plus tremelimumab in women with recurrent ovarian cancer and a germline BRCA1 or BRCA2 mutation: a phase I/II study
Related
- Olaparib tablets as maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a final analysis of a double-blind, randomised, placebo-controlled, phase 3 trial
- Adverse events in the placebo arm of SOLO2/ENGOT-Ov21 maintenance trial of olaparib in recurrent ovarian cancer
- Adjuvant olaparib for patients with germline BRCA-mutated, high-risk, HER2-negative early breast cancer: real-world data from a French early access program.
- Phase I/II Study of the PARP Inhibitor Olaparib and Irinotecan in Children and Young Adults with Recurrent/Refractory Malignancies: Arm D of the AcSé-ESMART Trial
- Efficacy and safety of maintenance olaparib and bevacizumab in ovarian cancer patients aged ≥65 years from the PAOLA-1/ENGOT-ov25 trial
BibTeX
@article{adams2026olaparib,
title = {{Olaparib plus tremelimumab in women with recurrent ovarian cancer and a germline BRCA1 or BRCA2 mutation: a phase I/II study}},
author = {Sarah F. Adams and Phyllis A. Gimotty and Teresa L. Rutledge and David M. O’Malley and Kari Ring and Robert M. Wenham and Karen Finkelstein and Elizabeth Lokich and Daniel M. Falcon and Alyson Yeckes and Olufunmilola M. Oyebamiji and Kathryn J. Brayer and Eleanor Paskus and Nadja K. Falk and Ryland Richards and Ji-Hyun Lee and Steven C. Eberhardt and Dennis McCance and Xavier Paliard and Sean Boyle and Richard Chen and Huining Kang and Jose R. Conejo-Garcia and Olivier Rixe and Carolyn Y. Muller},
journal = {Nature Communications},
year = {2026},
month = oct,
doi = {10.1038/s41467-026-78395-y},
url = {https://www.nature.com/articles/s41467-026-78395-y},
note = {CC BY-NC-ND 4.0},
}
RIS
TY - JOUR
TI - Olaparib plus tremelimumab in women with recurrent ovarian cancer and a germline BRCA1 or BRCA2 mutation: a phase I/II study
AU - Sarah F. Adams
AU - Phyllis A. Gimotty
AU - Teresa L. Rutledge
AU - David M. O’Malley
AU - Kari Ring
AU - Robert M. Wenham
AU - Karen Finkelstein
AU - Elizabeth Lokich
AU - Daniel M. Falcon
AU - Alyson Yeckes
AU - Olufunmilola M. Oyebamiji
AU - Kathryn J. Brayer
AU - Eleanor Paskus
AU - Nadja K. Falk
AU - Ryland Richards
AU - Ji-Hyun Lee
AU - Steven C. Eberhardt
AU - Dennis McCance
AU - Xavier Paliard
AU - Sean Boyle
AU - Richard Chen
AU - Huining Kang
AU - Jose R. Conejo-Garcia
AU - Olivier Rixe
AU - Carolyn Y. Muller
PY - 2026
DA - 2026/10/08
JO - Nature Communications
DO - 10.1038/s41467-026-78395-y
UR - https://www.nature.com/articles/s41467-026-78395-y
SN - 2041-1723
ER -